



September 4, 2026

Company Name: GNI Group Ltd.
 Representative: Director, Representative Executive Officer,
 President and CEO
 Ying Luo, PhD
 (Security Code: 2160, TSE Growth)
 Contact Person: Executive Officer, CSO
 Takuya Kaneko
 (TEL. 03-6214-3600)

Notice Regarding Executive Officer Appointments

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. (the “Company”) announces that, at a meeting of its Board of Directors held on September 4, 2026, the Board resolved to appoint a new Executive Officer and to change the responsibilities of an existing Executive Officer.

1. Change in Responsibilities of Executive Officer (Effective September 4, 2026)

Name	New Position	Previous Position
Ping Zhang	Director, Executive Officer and CBDO	Director and Executive Officer

CBDO: Chief Business Development Officer

2. Appointment of New Executive Officer (Effective September 4, 2026)

Name	Title and Responsibilities
Toshitaka Kawaratani	Executive Officer, Head of Business Development

3. Background of Appointment

In March 2026, Gyre Therapeutics, Inc., a consolidated subsidiary of the Company, completed the acquisition of Cullgen Inc. as a wholly owned subsidiary, followed by the Company’s acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. in July 2026. With these transactions, the Group has entered a new stage of growth toward becoming a global biopharmaceutical company. In Japan in particular, the Group aims to significantly expand its commercial platform and establish a large-scale healthcare platform capable of introducing innovative pharmaceuticals, biosimilars, internally developed products, and medical device products.

To advance these initiatives, the Company has newly appointed a CBDO to oversee Group-wide business development and synergy creation, while also welcoming Toshitaka Kawaratani as General Manager of the Business Development Division. Through this strengthened structure, the Group will promote closer collaboration among its domestic and overseas group companies, identify new business opportunities, pursue partnerships with external companies, and advance product in-licensing and other business development activities.

4. Comment from Ping Zhang, Director, Executive Officer and CBDO

“I am deeply honored to have been appointed Chief Business Development Officer (CBDO).

GNI Group has a unique business platform spanning Japan, the United States, and China, as well as a diverse range of growth opportunities. Going forward, I look forward to bringing together the strengths of our group companies and creating new value and growth opportunities through business development, strategic partnerships, and M&A.

I am fully committed to contributing to GNI Group’s continued growth as a global healthcare company and to enhancing its long-term corporate value.”

5. Comment from Toshitaka Kawaratani, Executive Officer and Head of Business Development

“I have built my career across a major Japanese pharmaceutical company, a global specialty biopharmaceutical company, and a leading CRO, with particular strengths in R&D, business planning, and business development. In these roles, I have been involved in management and have executed growth strategies by leveraging my international experience.

GNI Group is entering a new phase of growth this year with Ayumi Pharmaceutical joining the Group, while also having Gyre as a key overseas platform for R&D and growth. I believe the Group has significant potential for innovation and further expansion.

In addition to building on the Group’s existing strengths in fibrosis and expanding the business centered on Ayumi Pharmaceutical, I see substantial opportunities to broaden our therapeutic areas through Gyre’s innovation, pursue new partnerships, and leverage these capabilities globally, including in Japan. By driving business growth in Japan while expanding the Group’s global operations, I hope to contribute to GNI Group’s continued development as a pharmaceutical company capable of achieving significant growth on the global stage.

Joining the Company at this important stage represents both an exciting opportunity and a meaningful challenge. I look forward to contributing to patients in Japan and around the world, as well as to GNI Group’s stakeholders and the broader development of the healthcare industry in Japan and globally.”

6. Biography of Toshitaka Kawaratani

April 1988	Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Company, Limited)
April 1996	Head of Basel Representative Office, Sankyo Co., Ltd. (Switzerland)
April 1997	Assigned to Sankyo Europe GmbH
April 2001	Associate Director, Product Strategy Department and Licensing Department, Sankyo Co., Ltd.
January 2008	Head of Business Planning Division, UCB Japan Co., Ltd.; Member of Japan Executive Committee

March 2017	Senior Executive Officer, CMIC HOLDINGS Co., Ltd.; concurrently Deputy President and Executive Officer, CMIC Co., Ltd.
October 2022	Partner, Consulting and Navigation Unit, CMIC HOLDINGS Co., Ltd.
September 2026	Joined the Company as Executive Officer and General Manager of Business Development Division